



BME - GROWTH

Palacio de la Bolsa
Plaza de la Lealtad, 1
28014 Madrid

Alicante, 6th of July 2022

COMMUNICATION – FACEPHI BIOMETRIA, S.A.

Dear Sirs,

By virtue of the provisions of Article 17 of Regulation (EU) No 596/2014 on market abuse and Article 227 of the consolidated text of the Securities Market Law, approved by Royal Legislative Decree 4/2015, of 23 October, and concordant provisions, as well as in Circular 3/2020 of BME Growth of BME MTF Equity, we inform you of the following information relating to the company FACEPHI BIOMETRIA, S.A. (hereinafter "FacePhi" or "the Company" indistinctly).

OTHER RELEVANT INFORMATION

The Company will publish a preview of first 2022 semester's financial statements, the following 5th of August, before market opening.

In compliance with the provisions of Circular 3/2020 of the BME Growth segment of BME MTF Equity, it is expressly stated that the information communicated herein has been prepared under the sole responsibility of the Company and its directors.

We remain at your disposal for as many clarifications as you deem appropriate.

Kind regards

Javier Mira Miró

Chairman of the Board of Directors